Skip to content

Effectiveness of cognitive remediation in schizophrenia

Effectiveness of a computerized cognitive remediation program on cognitive functioning of patients with schizophrenic disorders: A randomized controlled study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016011810782N2
Enrollment
62
Registered
2016-05-28
Start date
2016-02-04
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Schizoaffective Disorder. Condition 2: Schizophrenia. Schizoaffective disorder Schizophrenia

Interventions

Intervention 1: Computer assisted cognitive remediation that consists of 10 training sessions using tasks in Cogpack software for improvement of memory, attention and executive functions. Sessions are
Rehabilitation
Treatment - Other
Computer assisted cognitive remediation that consists of 10 training sessions using tasks in Cogpack software for improvement of memory, attention and executive functions. Sessions are delivered in 2-
Treatment-as-usual that usually consists of antipsychotic medications in standard maintenance dosage prescribed by a physician and accompanied by patient education.

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with DSM-IV schizophrenia or schizoaffective disorder, aged 18 to 55 years and with education not less than 3rd grade in guidance school. Patients will be clinically stable and not acutely psychotic (Clinical Global Impression scale score less than 4, and Positive and Negative Syndrome Scale score less than 50). The dosage and the type of antipsychotic medications patients will receive at least during the three weeks prior to the study will be unchanged. At least 12 hours before the intervention, patients will receive their last dose of a benzodiazepine (if any) but no antihistamine medication will be administered. Exclusion criteria: Receiving electroconvulsive therapy (ECT) within six weeks prior to the study, mental retardation, uncorrected visual impairment, concurrent consumption of substances with the exception of nicotine and caffeine, a history of head trauma followed by loss of consciousness, suffering from a major neurological disorder (including epilepsy, Parkinson’s disease, dementia, multiple sclerosis, or any motor disability), severe worsening of illness during study requiring a change in medical treatments.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Executive function. Timepoint: Before and after the intervention. Method of measurement: CANTAB Battery.;Attention. Timepoint: Before and after the intervention. Method of measurement: CANTAB Battery.;Memory. Timepoint: Before and after the intervention. Method of measurement: CANTAB Battery.

Secondary

MeasureTime frame
Global Function. Timepoint: Before and after the intervention. Method of measurement: Global Assessment of Functioning.;Quality of life. Timepoint: Before and after the intervention. Method of measurement: Quality of life questionnaire.;Severity of illness. Timepoint: Before and after the intervention. Method of measurement: Positive and Negative Syndrome Scale, and Clinical global impression.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzadeh Sedighnia

Roozbeh Hospital

Azadehsedighnia@yahoo.com+98 21 5541 9151

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026